5-HT2C agonists as therapeutics for the treatment of schizophrenia

Handbook of Experimental Pharmacology

Volumn 213, Issue , 2012, Pages 147-165

  Rosenzweig Lipson, Sharon ^a,b   Comery, Thomas A ^a   Marquis, Karen L ^a   Gross, Jonathan ^a   Dunlop, John ^a,c  

^a PFIZER INC   (United States)

^b IVS Pharma Consulting LLC   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

5 HT2C agonists; Extrapyramidal symptoms; RNA editing; Schizophrenia; Vabicaserin; Weight gain

Indexed keywords

1 [3 FLUORO 5 (3 PYRIDYL)PHENYLCARBAMOYL] 5 METHOXY 6 TRIFLUOROMETHYLINDOLINE; 1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA[B][1,4]DIAZEPINO[6,7,1 HI]INDOLE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; ARIPIPRAZOLE; BENZAZEPINE DERIVATIVE; CP 809101; CYCLOALKYLDIAZEPINOINDOLE DERIVATIVE; INDOLE DERIVATIVE; INDOLINE DERIVATIVE; LORCASERIN; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PRX 000933; PRX 00933; QUINOLINE DERIVATIVE; RACLOPRIDE; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; VABICASERIN; FUSED HETEROCYCLIC RINGS; SEROTONIN 2 AGONIST;

ARTICLE; BRAIN TISSUE; DRUG EFFICACY; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; GENETIC VARIABILITY; HUMAN; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RNA EDITING; SCHIZOPHRENIA; SIDE EFFECT; SIGNAL TRANSDUCTION; TARDIVE DYSKINESIA; WEIGHT GAIN; REVIEW; TRANSLATIONAL RESEARCH;

HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; RNA EDITING; SCHIZOPHRENIA; SEROTONIN 5-HT2 RECEPTOR AGONISTS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84868305215     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-25758-2_6     Document Type: Article

References (87)

1. 2c receptor protein in human and rat brain using specific antisera. Neuropharmacology 24:1635-1645
2. Al-Janabi I, Arranz M, Blakemore A, Saiz P, Susce M, Glaser P, Clark D, de Leon J (2009) Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet 19:305-311
3. Anderson I, Clark L, Elliott R, Kulkarni B, Williams S, Deakin J (2002) 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI. Neuroreport 13:1547-1551 (Pubitemid 34970155)
4. Bagdy G, Makara G (1995) Paraventricular nucleus controls 5-HT2C receptor-mediated cortico-sterone and prolactin but not oxytocin and penile erection responses. Eur J Pharmacol 275:301-305
5. Berg KA, Dunlop J, Sanchez T, Silva M, Clarke WP (2008) A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin2C receptor alters both ligand-dependent and -independent receptor signaling. J Pharmacol Exp Ther 324:1084-1092 (Pubitemid 351397836)
6. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104 (Pubitemid 28337591)
7. Blackburn TP, Minabe Y, Middlemiss DN, Shirayama Y, Hashimoto K, Ashby CR Jr (2002) Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: An in vivo extracellular single cell study. Synapse 46:129-139 (Pubitemid 35155166)
8. Blackburn TP, Suzuki K, Ashby CR Jr (2006) The acute and chronic administration of the 5-HT (2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: an in vivo extracellular single cell study. Synapse 59:502-512
9. Chagnon YC (2006) Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets 7:1681-1695 (Pubitemid 44873730)
10. 2c receptor agonist and d-fenfluramine on feeding patterns in the rat. Psychopharmacology 152:256-267
11. Damjanoska K, Muma N, Zhang Y, D'Souza D, Garcia F, Carrasco G, Kindel G, Haskins K, Shankaran M, Petersen B, Van De Kar L (2003) Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol-l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine(2C) receptor agonist. J Pharmacol Exp Ther 304:1209-1216 (Pubitemid 36254434)
12. Di Giovanni G, De Deurwaerdere P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U (1999) Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopa-minergic function: a combined in vivo electrophysiological and microdialysis study. Neuro-science 91:587-597 (Pubitemid 29193268)
13. Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E (2000) Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53-61
14. Di Matteo V, Cacchio M, Di Giulio C, Esposito E (2002) Role of serotonin(2C) receptors in the control of brain dopaminergic function. Pharmacol Biochem Behav 71:727-734 (Pubitemid 34219223)
15. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1998) Selective blockade of serotonin2C/ 2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology 37:265-272 (Pubitemid 28293766)
16. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1999) SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38:1195-1205 (Pubitemid 29292408)
17. Dracheva S, Elhakem SL, Marcus SM, Siever LJ, McGurk SR, Haroutunian V (2003) RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia. J Neurochem 87:1402-1412 (Pubitemid 38020574)
18. Drago A, Serretti A (2009) Focus on HTR2C: a possible suggestion for genetic studies of complex disorders. Am J Med Genet 150B:601-637
19. Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, Sukoff S, Vogel RL, Stack G, Schechter L, Harrison BL, Rosenzweig-Lipson S (2005) WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b] [1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther 313:862-869 (Pubitemid 40604189)
20. Egerton A, Ahmad R, Hirani E, Grasby P (2008) Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. Psycho-pharmacology (Berl) 200:487-496
21. Ellenbroek BA (2004) Pre-attentive processing and schizophrenia: animal studies. Psychophar-macology (Berl) 174:65-74 (Pubitemid 38925092)
22. Ellingrod V, Perry P, Lund B, Bever-Stille K, Fleming F, Holman T, Miller D (2002) 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J Clin Psychopharmacol 22:622-624 (Pubitemid 35416790)
23. Ellingrod V, Perry P, Ringold J (2005) Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 134:76-78 (Pubitemid 40411114)
24. Fletcher P, Tampakeras M, Sinyard J, Higgins G (2007) Opposing effects of 5-HT2A and 5-HT2C receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test. Psychopharmacology 195:223-234 (Pubitemid 350045843)
25. Frank M, Stryker M, Tecott L (2002) Sleep and sleep homeostasis in mice lacking the 5-HT2c receptor. Neuropsychopharmacology 27:869-873 (Pubitemid 35335903)
26. Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, Millan MJ (2000) Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205-221 (Pubitemid 30252995)
27. Gunes A, Dahl M-L, Spina E, Scordo MG (2008) Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 64:477-482
28. Gunes A, Scordo M, Jaanson P (2007) Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psycho-pharmacology 190:479-484 (Pubitemid 46204465)
29. Heisler LK, Chu HM, Tecott LH (1998) Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Ann N Y Acad Sci 861:74-78 (Pubitemid 29047701)
30. Herrick-Davis K, Grinde E, Niswender CM (1999) Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. J Neurochem 73:1711-1717 (Pubitemid 29440175)
31. Herrick-Davis K, Grinde E, Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 295:226-232
32. Hill MJ, Reynolds GP (2007) 5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity. Brain Res 1149:14-17 (Pubitemid 46661934)
33. Hoffman B, Mezey E (1989) Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain. FEBS Lett 247:453-462 (Pubitemid 19129297)
34. Ikram H, Samad N, Haleem DJ (2007) Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia. Pak J Pharm Sci 20:188-195
35. Kawahara Y, Grimberg A, Teegarden S, Mombereau C, Liu S, Bale T, Blendy J, Nishikura K (2008) Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J Neurosci 28:12834-12844
36. Kenakin T (1995) Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238
37. Kostrzewa RM, Huang N-Y, Kostrzewa JP, Nowak P, Brus R (2007) Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment. Neurotox Res 11:41-50
38. 2C-selective ligands for possible use in schizophrenia. ChemMedChem 5:1221-1225
39. Kuzman M, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H (2008) The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 160:308-315
40. Lacivita E, Leopoldo M (2006) Selective agents for serotonin2C (5-HT2C) receptor. Curr Top Med Chem 6:1927-1970 (Pubitemid 44524470)
41. Marazziti D, Rossi A, Giannaccini G, Zavaglia KM, Dell'Osso L, Lucacchini A, Cassano GB (1999) Distribution and characterization of [3H]mesulergine binding in human brain postmortem. Eur Neuropsychopharmacol 10:21-26
42. 2C receptor agonist possessing atypical antipsychotic-like effects in preclinical models. Program No 934, Neuroscience Meeting Planner Atlanta, GA: Society for Neuroscience
43. Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a- octahydro-7bH-cyclopenta-[b][1,4] diazepino[6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486-496 (Pubitemid 46025760)
44. Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HH, Broekkamp CL, Ruigt GS, Kohler C, Delft AM (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913-924 (Pubitemid 29003485)
45. Masellis M, Basile V, Meltzer H, Lieberman J, Sevy S, Macciardi F, Cola P, Howard A, Badri F, Nothen M, Kalow W, Kennedy JL (1998) Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19:123-132 (Pubitemid 28288438)
46. Mayers A, Baldwin D (2005) Antidepressants and their effect on sleep. Hum Psychopharmacol Clin Exp 20:533-559 (Pubitemid 43056116)
47. Meltzer H, Maes M (1995) Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. Biol Psychiatry 385:310-318
48. Miller KJ (2005) Serotonin 5-HT2C receptor agonists: potential for the treatment of obesity. Mol Interv 5:282-291 (Pubitemid 41595460)
49. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104 (Pubitemid 40139590)
50. Mombereau C, Kawahara Y, Gundersen B, Nishikura K, Blendy J (2010) Functional relevance of serotonin 2C receptor mRNA editing in antidepressant- and anxiety-like behaviors. Neuro-pharmacology 59:468-473
51. Morris E, Normandin M, Schiffer W (2008) Initial comparison of ntPET with microdialysis measurements of methamphetamine-induced dopamine release in rats: support for estimation of dopamine curves from PET data. Mol Imaging Biol 10:67-73
52. Morris E, Yoder K, Wang C, Normandin M, Zheng Q, Mock B, Muzic RJ, Froehlich J (2005) ntPET: a new application of PET imaging for characterizing the kinetics of endogenous neurotransmitter release. Mol Imaging 4:473-489 (Pubitemid 43143787)
53. Müller D, Kennedy JL (2006) Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 7:863-887 (Pubitemid 44446736)
54. Navarra R, Comery TA, Graf R, Rosenzweig-Lipson S, Day M (2008) The 5-HT2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test. Behav Brain Res 188:412-415
55. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E (1999) RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 274:9472-9478
56. Niswender CM, Herrick-Davis K, Dilley GE, Meltzer HY, Overholser JC, Stockmeier CA, Emeson RB, Sanders-Bush E (2001) RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychophar-macology 24:478-491 (Pubitemid 32244309)
57. Niswender CM, Sanders-Bush E, Emeson RB (1998) Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann N Y Acad Sci 861:38-48 (Pubitemid 29047697)
58. Nonogaki K, Strack A, Dallman M, Tecott L (1998) Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 4:1152-1156 (Pubitemid 28468828)
59. Park Y, Cho J, Kang S, Choi J, Lee S, Kim L, Lee H (2008) Lack of association between the - 759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. J Clin Pharm Ther 33:55-60
60. Ramamoorthy P, Beyer C, Brennan J, Dunlop J, Gove S, Grauer S, Harrison BL, Lin Q, Malberg J, Marquis K, Mazandarani H, Piesla M, Pulicicchio C, Rosenzweig-Lipson S, Sabb A-M, Schechter L, Stack G, J Z (2006) Discovery of SCA-136, a novel 5-HT2C agonist, for the treatment of schizophrenia. 231st American Chemical Society National Meeting: MEDI-021
61. Rauser L, Savage JE, Meltzer HY, Roth BL (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299:83-89 (Pubitemid 32905121)
62. Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (1999) Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol 126:572-574 (Pubitemid 29087833)
63. Reynolds G, Zhang Z, Zhang X (2002) Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359:2086-2087 (Pubitemid 34680975)
64. Reynolds GP, Templeman LA, Zhang ZJ (2005) The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 29:1021-1028 (Pubitemid 41080129)
65. Rietschel M, Naber D, Finmmers R, Moller H, Propping P, Nothen M (1997) Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 8:1999-2003 (Pubitemid 27314324)
66. Robinson ESJ, Dalley JW, Theobald DEH, Glennon JC, Pezze MA, Murphy ER, Robbins TW (2007) Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. Neuropsychophar-macology 33:2398-2406
67. Rosenzweig-Lipson S, Beyer C, Hughes Z, Lin Q, Zhang M-Y, Grauer S, Comery T, Aschmies S, Stack G, Marquis K (2007a) Vabicaserin: Effects of a novel 5-HT2C agonist on prefrontal cortical neurotransmission, cognition and sensorimotor gating. European Neuropsychophar-macology The Journal of the European College of Neuropsychopharmacology 17(Supl.4):S484
68. Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg JE, Grauer S, Brennan J, Cryan JF, Sukoff Rizzo SJ, Dunlop J, Barrett JE, Marquis KL (2007b) Antidepressant-like effects of the novel, selective, 5-HT(2C) receptor agonist WAY-163909 in rodents. Psycho-pharmacology 192:159-170 (Pubitemid 46669211)
69. Rosenzweig-Lipson S, Zhang J, Mazandarani H, Harrison BL, Sabb A, Sabalski J, Stack G, Welmaker G, Barrett JE, Dunlop J (2006) Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res 1073-1074:240-251
70. Sabb AL, Vogel RL, Welmaker GS, Sabalski JE, Coupet J, Dunlop J, Rosenzweig-Lipson S, Harrison B (2004) Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor. Bioorg Med Chem Lett 14:2603-2607 (Pubitemid 38515711)
71. Sargent P, Sharpley A, Williams C, Goodall E, Cowen P (1997) 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133:309-312 (Pubitemid 27445666)
72. Segman R, Heresco-Levy U, Finkel B (2000) Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology 152:408-413
73. Sharpley A, Soloman R, Fernando A, da Roza DJ, Cowen P (1990) Dose-related effects of selective 5-HT2 receptor antagonists on slow wave sleep in humans. Psychopharmacology (Berl) 101(4):568-569 (Pubitemid 20220053)
74. Sharpley A, Vassaollo C, Cowen P (2000) Olanzapine increases slow-eave sleep; evidence for blockade of central 5-HT2c receptors in vivo. Biol Psychiatry 47:468-470 (Pubitemid 30110618)
75. Shen et al. (2011) Neuropsychopharmacology 36:S75-S197. doi:10.1038/npp.2011.291
76. Shilliam CS, Dawson LA (2005) The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT2C receptor antagonist. Neuropsychopharmacology 30:372-380 (Pubitemid 40129488)
77. Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA (2007) CP-809,101, a selective 5-HT(2C) agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52:279-290 (Pubitemid 46123348)
78. Sodhi MS, Burnet PW, Makoff AJ, Kerwin RW, Harrison PJ (2001) RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia. Mol Psychiatry 6:373-379 (Pubitemid 32566085)
79. Stark J, McKie S, Davies K, Williams S, Luckman S (2008) 5-HT(2C) antagonism blocks blood oxygen level-dependent pharmacological-challenge magnetic resonance imaging signal in rat brain areas related to feeding. Eur J Neurosci 27:457-465 (Pubitemid 351147701)
80. 2c serotonin receptors. Nature 374:542-546
81. Templeman L, Reynolds G, Arranz B, San L (2005) Polymorphisms of the 5HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 15:195-200 (Pubitemid 40569890)
82. Tsuno N, Besset A, Ritchie K (2005) Sleep and depression. J Clin Psychiatry 66:1254-1269 (Pubitemid 41546505)
83. Winstanley CA, Theobald DEH, Dalley JW, Glennon JC, Robbins TW (2004) 5-HT 2A and 5-HT 2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology 176:376-385 (Pubitemid 40012745)
84. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN (2006) Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets 5:445-452 (Pubitemid 44203355)
85. Yevtushenko O, Cooper S, O'Neill R, Doherty J, Woodside J, Reynolds G (2008) Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 192:424-428 (Pubitemid 351809894)
86. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (2006) Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 71:521-529 (Pubitemid 43077085)
87. Zhang Z, Zhang X, Sha W (2002) Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 7:670-671 (Pubitemid 34984941)